With proteomic tools, we have shown that the serum level of the anti-LIMS1 autoantibody is significantly increased in pathologic myopia and is a potential serum biomarker for this disease, supporting a previously unrecognized autoimmune aspect of the pathogenesis of pathologic myopia. Here, LIMS1 is linked to myopia.